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Pioglitazone in Nonalcoholic Steatohepatitis
To the Editor: Belfort and colleagues (Nov. 30 
issue)1 report on the efficacy of 6 months of treat-
ment with pioglitazone with respect to the histo-
logic severity of nonalcoholic steatohepatitis. I 
agree with the authors’ conclusion that the results 
serve as “proof of concept” that pioglitazone leads 
to histologic improvement in patients with this 
condition.
These results apply to nonalcoholic steato-
hepatitis in patients with type 2 diabetes melli-
tus or impaired glucose tolerance; however, they 
may not apply to the general population of pa-
tients with nonalcoholic steatohepatitis. Indeed, 
although this condition is frequently associated 
with obesity and type 2 diabetes, only one third 
of people with nonalcoholic steatohepatitis have 
type 2 diabetes.2-4
Moreover, it would be interesting to know 
whether pioglitazone is equally effective in im-
proving the hepatic histologic findings in patients 
with type 2 diabetes and in those with impaired 
glucose tolerance. In the study by Belfort and col-
leagues, information on the exact proportion of 
patients with type 2 diabetes and of those with 
impaired glucose tolerance is lacking. Patients 
with type 2 diabetes have a higher risk of fibrosis 
and cirrhosis than do patients who do not have 
diabetes.2-4 Thus, the efficacy of pioglitazone in 
reducing the severity of nonalcoholic steatohepa-
titis might be different among patients with type 
2 diabetes than among those with impaired glu-
cose tolerance.
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To the Editor: The study by Belfort et al. shows 
a significant effect of pioglitazone, as compared 
with placebo, for the treatment of nonalcoholic 
steatohepatitis. However, the average weight re-
duction was only 0.5 kg over a 6-month period in 
subjects in the placebo group; this may explain 
the lack of improvement in indicators of nonalco-
holic steatohepatitis in these subjects. Thus, the 
ineffective diet and exercise program could have 
led to an overestimation of the effect of pioglit-
azone. Belfort and colleagues attempt to address 
this limitation by showing that there was no he-
patic histologic improvement in 12 subjects who 
were assigned to placebo and who lost a mean 
(±SD) of 3.2±0.5 kg. This sample size may lack 
the power to detect differences. Also, the authors 
cite a meta-analysis that reported the variable ef-
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fects of weight reduction in patients with nonalco-
holic steatohepatitis; however, the analysis showed 
consistent improvement in liver measurements 
after weight reduction.1 The standard treatment 
for nonalcoholic steatohepatitis and other obesity-
related diseases is weight reduction, achieved 
through concurrent diet and exercise.2,3 It is im-
possible to predict what the real difference would 
have been if the subjects in the placebo group had 
lost weight. Future research regarding nonalcoholic 
steatohepatitis will require comprehensive pro-
grams of diet and exercise to estimate accurately 
the effects of drugs over standard treatment.
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To the Editor: In their placebo-controlled trial, 
Belfort et al. show that pioglitazone leads to im-
provement in subjects with nonalcoholic steatohep-
atitis by reducing insulin resistance and suppress-
ing cytokine-mediated inflammation. However, it 
is not clear whether the beneficial effect of pio-
glitazone occurs through improved insulin sensi-
tivity or its direct antiinflammatory effect on the 
liver.
Recently we established an animal model of 
steatohepatitis in which the pathological abnor-
malities are exacerbated by insulin resistance and 
obesity-related diabetes.1 In this model, pioglit-
azone inhibits the activation of stellate cells, 
which play a central role in hepatic fibrosis, prob-
ably by down-regulating the hepatic expression of 
transforming growth factor β and inflammatory 
cytokines. The improvement in the pathological 
findings as a result of the antiinflammatory ef-




ing in obese animals with diabetes than in non-
obese animals without diabetes, indicating that 
the effect of pioglitazone occurs mainly through 
improved insulin resistance.
Therefore, a larger clinical trial is needed to 
clarify whether pioglitazone ameliorates the path-
ological features of nonalcoholic steatohepatitis in 
patients with and in those without insulin resis-
tance. This point is especially relevant if made-to-
order pioglitazone therapy is anticipated for pa-
tients with nonalcoholic steatohepatitis.
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The Authors Reply: Targher asks about the pro-
portions of patients with type 2 diabetes and of 
those with impaired glucose tolerance in our study. 
In the pioglitazone group, 13 patients had impaired 
glucose tolerance, and 14 had type 2 diabetes. In 
the placebo group, 12 patients had impaired glu-
cose tolerance, and 9 had type 2 diabetes. We think 
that the proportion of patients with nonalcoholic 
steatohepatitis and undiagnosed impaired glucose 
tolerance or type 2 diabetes is much higher than 
previously appreciated. In our study, all patients 
underwent a screening oral glucose tolerance test, 
and 8 of 23 patients received a new diagnosis of 
type 2 diabetes this way. Among the other 25 pa-
tients with a diagnosis of impaired glucose toler-
ance (“prediabetes”), none were suspected of hav-
ing this condition. The histologic scores at baseline 
and the response to pioglitazone were similar, 
regardless of whether patients had impaired glu-
cose tolerance or type 2 diabetes. Reducing plas-
ma glucose levels with pioglitazone may be im-
portant in order to ameliorate hepatic lipogenesis 
(i.e., to reduce the activity of hepatic carbohy-
drate response-element–binding protein1). Future 
studies may determine whether pioglitazone is of 
greater benefit in patients with impaired glucose 
tolerance or type 2 diabetes.
We agree with Chavez-Tapia et al. that lifestyle 
modification and weight reduction are the corner-
stones of treatment for both type 2 diabetes and 
nonalcoholic steatohepatitis. However, we did 
not compare the effect of weight reduction (in the 
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placebo group) with the effect of pioglitazone 
treatment. The two groups received identical nu-
tritional counseling to reflect the current stan-
dards of care. Against this background, we com-
pared placebo with pioglitazone. Our results match 
those of the clinical-practice and lifestyle-interven-
tion studies that show the difficulties of achiev-
ing and maintaining weight loss in patients with 
nonalcoholic steatohepatitis. In the meta-analysis 
of 13 trials by Wang et al.,2 the studies were typi-
cally small (only 3 had >50 patients) and uncon-
trolled (10 were case series), and they frequently 
used a surrogate primary end point (i.e., liver ami-
notransferase levels in 8 of the 13 trials); steato-
sis was the only histologic improvement. As in 
our placebo group, improvement in aminotrans-
ferase levels does not necessarily translate into 
improved liver histologic scores. Recently, Huang 
et al.3 reported a trend toward a histologic ben-
efit but not a significant benefit of a year-long, 
intense nutritional counseling program in patients 
with nonalcoholic steatohepatitis. Weight reduc-
tion in their study (−2.9 kg) was similar to that in 
our patients in the diet-plus-placebo group who 
had a response to the study treatment (−3.2 kg). 
Moderate weight loss may improve liver histo-
logic results, but long-term controlled trials 
using histologic results as the primary end point 
are needed.
As suggested by Ota et al., pioglitazone not only 
may improve insulin resistance but may have di-
rect antiinflammatory effects on the liver. In our 
study, pioglitazone ameliorated systemic inflam-
mation by lowering plasma C-reactive protein, 
tumor necrosis factor α, transforming growth fac-
tor β, and intracellular adhesion molecule and 
vascular-cell adhesion molecule concentrations 
(unpublished data). Obesity and high-fat diets may 
activate the hepatic inhibitor of κB kinase β and 
nuclear factor-κB inflammatory pathways and 
promote insulin resistance.4 As Ota and colleagues 
suggest, more work is needed in this area.
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Bivalirudin in Acute Coronary Syndromes
to the editor: The main message of the study 
of bivalirudin in patients with acute coronary syn-
dromes, reported by Stone et al. (Nov. 23 issue)1 
is that, as compared with heparin or enoxaparin 
plus a glycoprotein IIb/IIIa inhibitor, bivalirudin 
alone offers a similar degree of protection against 
ischemic events and a significant reduction in 
bleeding complications. Most of the benefit of bi-
valirudin alone was associated with the lower rate 
of catheterization-related hemorrhage (0.8% with 
bivalirudin alone vs. 2.5% in the other two groups). 
Given the importance of bleeding complications 
for the interpretation of the results, it is surprising 
that no details on the arterial access used during 
the trial were provided, although the numbers re-
ported suggest a predominant use of the trans-
femoral approach. If this is true, considering that 
severe local arterial complications are rare when 
the radial artery is used for diagnostic or inter-
ventional procedures,2,3 probably little or no ben-
efit should be expected from bivalirudin in the 
setting of transradial catheterization. We still need 
better antithrombotic strategies for high-risk acute 
coronary syndromes, but the reduction of vascu-
lar complications is best accomplished by a wider 
application of the transradial technique.
Marcelo Sanmartin, M.D.
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